These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25522994)

  • 1. Dysfunctional HDL: from structure-function-relationships to biomarkers.
    Riwanto M; Rohrer L; von Eckardstein A; Landmesser U
    Handb Exp Pharmacol; 2015; 224():337-66. PubMed ID: 25522994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.
    Riwanto M; Landmesser U
    J Lipid Res; 2013 Dec; 54(12):3227-43. PubMed ID: 23873269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease.
    Kratzer A; Giral H; Landmesser U
    Cardiovasc Res; 2014 Aug; 103(3):350-61. PubMed ID: 24935432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDL and atherothrombotic vascular disease.
    Annema W; von Eckardstein A; Kovanen PT
    Handb Exp Pharmacol; 2015; 224():369-403. PubMed ID: 25522995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDL-C: clinical equipoise and vascular endothelial function.
    Campbell S; Genest J
    Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):343-53. PubMed ID: 23469914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the genetics of HDL: why is HDL cholesterol inversely related to cardiovascular disease?
    Kuivenhoven JA; Groen AK
    Handb Exp Pharmacol; 2015; 224():285-300. PubMed ID: 25522992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-density lipoproteins: marker of cardiovascular risk and therapeutic target.
    Toth PP; Davidson MH
    J Clin Lipidol; 2010; 4(5):359-64. PubMed ID: 21122679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.
    Gomaraschi M; Adorni MP; Banach M; Bernini F; Franceschini G; Calabresi L
    Handb Exp Pharmacol; 2015; 224():593-615. PubMed ID: 25523003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Laboratory assessment of HDL heterogeneity and function].
    Movva R; Rader DJ
    Ann Biol Clin (Paris); 2009; 67(1):7-21. PubMed ID: 19189882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein carbamylation and cardiovascular disease.
    Verbrugge FH; Tang WH; Hazen SL
    Kidney Int; 2015 Sep; 88(3):474-8. PubMed ID: 26061545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL-c is a powerful lipid predictor of cardiovascular diseases.
    Bruckert E; Hansel B
    Int J Clin Pract; 2007 Nov; 61(11):1905-13. PubMed ID: 17655681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL-cholesterol in coronary artery disease risk: function or structure?
    Pérez-Méndez Ó; Pacheco HG; Martínez-Sánchez C; Franco M
    Clin Chim Acta; 2014 Feb; 429():111-22. PubMed ID: 24333390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Low HDL-cholesterol--an important risk factor for cardiovascular diseases].
    Reiner Z; Muacević-Katanec D; Katanec D; Tedeschi-Reiner E
    Lijec Vjesn; 2011; 133(3-4):111-6. PubMed ID: 21612108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating cardiovascular disease risk factors and signaling in endothelial cell caveolae.
    Mineo C; Shaul PW
    Cardiovasc Res; 2006 Apr; 70(1):31-41. PubMed ID: 16540099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
    Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation alters HDL composition and function: implications for HDL-raising therapies.
    Marsche G; Saemann MD; Heinemann A; Holzer M
    Pharmacol Ther; 2013 Mar; 137(3):341-51. PubMed ID: 23246719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wine and cardiovascular disease.
    de Gaetano G; Cerletti C;
    Nutr Metab Cardiovasc Dis; 2001 Aug; 11(4 Suppl):47-50. PubMed ID: 11894753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium.
    Andrews KL; Moore XL; Chin-Dusting JP
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):736-42. PubMed ID: 20374256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.